TRPC5 and breast cancer: Similarly, Ma et al. observed that breast cancer cells exposed to adriamycin in vitro can increase the release of L-EVs containing the transient receptor potential channel 5 (TrpC5), namely a receptor-activated non-selective calcium permeant cation channel.